The acclaimed author is also an artist, has run a ranch, trained horses, done carpentry, played jazz guitar and mended ...

Patients are being warned to stop using some glucose monitors made by Abbott Diabetes Care after the company found malfunctioning sensors may be linked to hundreds of adverse events and several deaths ...

Abbott warned that about 3 million FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors are affected, but no other Libre products. Patients can visit FreeStyleCheck.com to see if their sensors are ...

Abbott has launched an effort to replace some of its FreeStyle Libre 3 continuous glucose monitors—following reports of hundreds of injuries and seven deaths worldwide—after some sensors showed they ...

Two decisions by the Texas governor this week, including directing authorities to investigate an Islamic organization, come as the state sees an increase in anti-Muslim rhetoric. By Ruth Graham Ruth ...

Exact Sciences Corporation stock surged after Abbott Laboratories announces a $21bn acquisition at $105 per share, driven by Exact's cancer diagnostics leadership. Exact Sciences boasts strong revenue ...

Abbott to buy Exact Sciences in $23 billion deal Exact's flagship colorectal cancer test to join Abbott's portfolio Abbott eyes international expansion for Exact's tests Aims for broad reimbursement ...

Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...

Abbott Laboratories ABT1.77%increase; green up pointing triangle agreed to acquire cancer diagnostics company Exact Sciences EXAS 0.14%increase; green up pointing triangle in a deal valued at about ...

In January, Exact Sciences CEO Kevin Conroy told us that 2025 was shaping up to be a transformative year for the diagnostics company. Three cancer test launches, multiple study readouts and one $23 ...

Abbott Laboratories (NYSE: ABT) agreed on Thursday to acquire cancer screening company Exact Sciences Corp (NASDAQ: EXAS) for $105 per common share, representing a total equity value of approximately ...

Abbott announced on Thursday, Nov. 20 it plans to buy Exact Sciences, a Madison-based maker of cancer screening and diagnostic tests, in a deal valued at an estimated $23 billion, including debt. The ...